
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday. A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Attending Physician, Thoracic Oncology Service Giannis Mountzios, MD, MSc, PhD Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center Athens, Greece,
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

LCC in Spanish: WCLC 2026 Highlights

LCC in Portuguese: WCLC 2026 Highlights

Live From WCLC 2026: Tuesday Highlights & Meeting Summary

LCC in Mandarin: WCLC 2026 Highlights
Free AI-powered recaps of Lung Cancer Considered and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.